Archive for December, 2022

Maze Therapeutics Announces Completion of Phase 1 First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease

Posted by amanda punzalan under Press (No Respond)

Maze Therapeutics Announces Completion of Phase 1 First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease MZE001 was Well-Tolerated and Reduced Glycogen Accumulation in Blood Cells in Healthy Volunteers, Supporting Advancement into Phase 2 Clinical Trial SOUTH…

Updated: Maze reveals positive first look at PhI Pompe disease candidate

Posted by amanda punzalan under Media (No Respond)